Efficacy and safety of itraconazole as empirical antifungal therapy in febrile neutropenic patients with hematologic malignancies： an open-lable, multicenter, observational trial in a Chinese cohort

• Published in: Chinese medical journal 2011-11, Vol.124 (22), p.3670-3675
• Main Authors: Cheng, Shu, Zhou, Jian-Feng, Zou, Ping, Huang, Xiao-Jun, Jin, Jie, Shen, Zhi-Xiang
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Antifungal Agents - adverse effects; Antifungal Agents - therapeutic use; Female; Hematologic Neoplasms - drug therapy; Hematologic Neoplasms - microbiology; Humans; Itraconazole - adverse effects; Itraconazole - therapeutic use; Male; Middle Aged; Neutropenia - drug therapy; Neutropenia - microbiology; Treatment Outcome; Young Adult; 中国人群; 中性粒细胞; 伊曲康唑; 发热性; 安全性; 恶性血液病; 抗真菌; 经验性
• ISSN: 0366-6999; 2542-5641
• DOI: 10.3760/cma.j.issn.0366-6999.2011.22.013

Background Invasive fungal infection （IFI） is a common and fatal complication in neutropenic patients with hematological malignancy. Empirical antifungal therapy is widely used in practice due to the difficulty of pathogens determination and illness of the hosts. The aim of this study was to evaluate the efficacy and safety of itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematologic malignancies. Methods Two hundred and seventy-four patients with hematologic malignancies who had suspected fungal infections were enrolled in 18 centers across China between April 2008 and April 2009. Empirical antifungal therapy with intravenous itraconazole 200 mg twice daily was given for the first two days, followed by 200 mg once daily for the next 12 days. Oral itraconazole solution was sequential for follow-up therapy if necessary. Five composite end points were evaluated for the response, which was more restrictive and adopted for the first time in such study in China. Results The intent-to-treat analysis included data from 274 patients （full analysis set, FAS）, of whom 248 were included as the per-protocol population （PPS）. As the composite end point of five indices was concerned, the overall response rate was 43.4%. Seperately, defervescence was achieved in 90% of patients in which 55.5% occured during neutropenia. The mean time to defervescence was 2.71 days. Absence of breakthrough IFI during drug administration or within the first 7 days after study completion was observed in 71.5% of patients. Fifty-five point five percent patients with IFI at baseline was successfully treated. Ninety point five percent patients survived for at least 7 days after completing the study. PPS analysis revealed that the duration of neutropenia 〉10 days was a statistically significant negative predictor for the response. The withdrawal rate due to drug-related toxicity or lack of efficacy was 11.0%. The incidence of adverse events was 22.6%, in which 11.6% was study drug related. The most frequent adverse events were mild to moderate liver toxicity. Conclusion Itraconazole shows desirable efficacy and safety as empirical antifungal therapy for febrile neutropenic patients with hematologic malignancies.